1921
Volume 103, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6 genetic polymorphisms that result in reduced or no enzyme activity. The distribution of CYP2D6 genotypes and predicted phenotypes in the Cambodian population is not well described. Surveys in other Asian countries have shown an approximate 50% prevalence of the reduced activity CYP2D6 allele *10, which could translate into increased risk of PQ radical cure failure and repeated relapses, making interruption of transmission and malaria elimination difficult to achieve. We determined CYP2D6 genotypes from 96 volunteers from Oddor Meanchey Province, Cambodia, an area endemic for . We found a 54.2% frequency of the *10 allele, but in approximately half of our subjects, it was paired with a normal activity allele, either *1 or *2. The prevalence of *5, a null allele, was 9.4%. Overall predicted phenotype percentages were normal metabolizers, 46%; intermediate metabolizers, 52%; and poor metabolizers, 1%.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0061
2020-05-11
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/2/tpmd200061.html?itemId=/content/journals/10.4269/ajtmh.20-0061&mimeType=html&fmt=ahah

References

  1. Siv S, Roca-Feltret A, Vinjamuri SB, Bouth DM, Lek D, Rashid M, By NP, Popovici J, Huy R, Menard D, 2016. Plasmodium vivax malaria in Cambodia. Am J Trop Med Hyg 95 (6 Suppl): 97107.
    [Google Scholar]
  2. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 13811382.
    [Google Scholar]
  3. Marcsisin SR, Reichard G, Pybus BS, 2016. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther 161: 110.
    [Google Scholar]
  4. Zhou SF, 2009. Polymorphisms of human cytochrome P450 2D6 and its clinical significance. Clin Pharm 48: 689723.
    [Google Scholar]
  5. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS, 2008. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234242.
    [Google Scholar]
  6. Clinical Pharmacogenetics Implementation Consortium (CPIC), 2019. Available at: https://cpicpgx.org/wp-content/uploads/2019/03/Final-Consensus-CYP2D6-genotype-to-phenotype-table_-final_Mar2019.pdf. Accessed October 31, 2019.
  7. Lon C et al., 2014. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One 9: e93138.
    [Google Scholar]
  8. Spring MD et al., 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15: 683691.
    [Google Scholar]
  9. Staehli Hodel EM, Csajka AF, Guidu M, Kabanywanyi AM, Duong S, Decosterd LA, Olliaro P, Beck HP, Genton B, 2013. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother 57: 950958.
    [Google Scholar]
  10. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S, 2007. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharm Genom 17: 93101.
    [Google Scholar]
  11. Chamnanphon M, Gaedigk A, Vanwong N, Nuntamool N, Hongkaew Y, Puangpetch A, Sukasem C, 2018. CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics 19: 947960.
    [Google Scholar]
  12. Puaprasert K, Chu C, Saralamba N, Day NPJ, Nosten F, White NJ, Dondorp AM, Imwong M, 2018. Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen populations study. Malar J 17: 247.
    [Google Scholar]
  13. Love RR et al., 2013. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. SpringerPlus 2: 52.
    [Google Scholar]
  14. Nguyen HH, Ma TTH, Vu NP, Bach QTN, Vu TH, Nguyen TD, Nong HV, 2019. Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population. Medicine 98: e15891.
    [Google Scholar]
  15. St. Jean PL et al., 2016. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J 15: 97.
    [Google Scholar]
  16. Chamnanphon M, Gaedigk A, Puangpetch A, Pasomsub E, Chantratita W, Longley RJ, Sattabongkot J, Chariyavilaskul P, Sukasem C, 2020. Pharmacogene variation in Thai Plasmodium vivax relapse patients treated with a combination of primaquine and chloroquine. Pharmacogenomics Pers Med 13: 112.
    [Google Scholar]
  17. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS, 2017. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19: 6976.
    [Google Scholar]
  18. Baird JK et al., 2018. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Netw Open 1: e181449.
    [Google Scholar]
  19. Spring MD et al., 2019. Determination of cytochrome P-450 isoenzyme 2D6 (CYP2D6) genotypes and the pharmacogenomic impact on primaquine metabolism in an active-duty U.S. Military population. J Infect Dis 220: 17611770.
    [Google Scholar]
  20. Baird JK, 2019. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev 32: e00011.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0061
Loading
/content/journals/10.4269/ajtmh.20-0061
Loading

Data & Media loading...

  • Received : 23 Jan 2020
  • Accepted : 29 Mar 2020
  • Published online : 11 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error